Cell Innovation Partners - Investor Profile and Portfolio

Developer of compounds to protect against tissue degradation and promote healing during illness or injury. The pipeline candidates include SB-061 for osteoarthritis, and SB-0303 for peripheral vascular disease/vein graft failure, fibrosis, and cancer.

Steminent Biotherapeutics is a company engaged in the R&D of cellular therapeutics for diseases with unmet needs, based on their expertise in the know-how of isolation, purification, and amplification of standardized stem cell products. The company has developed a validated platform (Stemchymal) of allogeneic stem cells which initially target neurodegenerative and other degenerative diseases. The company's proprietary cell processing system can be used for the isolation of multipotent stem cells from a number of somatic tissues (adipose). The company is currently conducting autologous mesenchymal stem cells based Phase I/II clinical trial for treating Osteoarthritic Knee (NCT02544802) and a randomized, double-blind/placebo-controlled phase II clinical trial (NCT02540655) for PolyQ Spinocerebellar Ataxia (SCA), which also has an orphan drug destination.

Elastagen is a clinical stage medical company with a pipeline of formulation products based on the human protein tropoelastin.The company was founded after the acquisition of the Elastin technology from its founding scientist Prof Weiss (who is also the company's Lead Scientific Advisor) and his team at the University of Sydney. The Elastin technology offers a new pathway to produce a synthetic, identical and recombinant version of the naturally found "tropoelastin", the building blocks of elastin, a critical component in tissues responsible for the ability of lungs, skin, arteries and other elastic ligaments to stretch and recoil. The company claims that it is the first and only provider of commercial cGMP clinical grade human tropoelastin which can be used to support cell growth and tissue repair. Elastagen also claims the recombinant tropoelastin has an ideal biocompatibility profile and no immune rejection problems. Currently, the company is conducting pivotal clinical studies an injectable dermo-aesthetic product that supposedly restores the elasticity of the skin. In addition, it is investigating solutions for Atrophic Scars, Scar Revision and wound healing. Elastagen claims that its technology has potential applications in skin rejuvenation, scar remodelling and tissue repair. The company also has operations in Europe and UK.